Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long enduring response on teclistamab in a patient with myeloma relapse after allogeneic hematopoietic stem cell transplantation - a case report.

Annals of hematology·2026
Same author

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Leukemia·2026
Same author

The spatio-functional cortical representation of muscles innervated by the accessory nerve using nTMS.

Clinical neurophysiology practice·2025
Same author

Molecular diagnostics in cancer patients with suspected respiratory mold infections.

Journal of clinical microbiology·2025
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Long-term complete remissions of refractory severe idiopathic immune thrombocytopenia treated with daratumumab: A case series.

British journal of haematology·2024

Related Experiment Video

Updated: May 9, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

[Multiple myeloma].

K M Kortüm1, M Engelhardt, L Rasche

  • 1Division of Hematology, Mayo Clinic Arizona, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA. kortum.klausmartin@mayo.edu

Der Internist
|July 18, 2013
PubMed
Summary
This summary is machine-generated.

Multiple myeloma (MM) is a cancer of plasma cells. Diagnosis involves detecting monoclonal proteins, and treatment combines chemotherapy with novel drugs like bortezomib.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: May 9, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Context:

  • Multiple myeloma (MM) is a plasma cell malignancy, a type of non-Hodgkin lymphoma.
  • Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition requiring monitoring.
  • MM diagnosis involves detecting M components (immunoglobulins or free light chains) in serum/urine.

Purpose:

  • To outline the characteristics, diagnosis, and treatment of multiple myeloma.
  • To differentiate MM from MGUS and highlight the importance of follow-up for MGUS.

Summary:

  • MM originates from terminally differentiated B lymphocytes (plasma cells).
  • Diagnosis involves quantifying monoclonal proteins, blood counts, renal function tests, skeletal imaging, and bone marrow biopsy.
  • Key therapies include melphalan or cyclophosphamide combined with novel agents (bortezomib, thalidomide, lenalidomide).

Impact:

  • Improved understanding of MM and MGUS diagnosis and management.
  • Highlights the role of novel drugs in MM therapy.
  • Provides a concise overview for clinicians and researchers in hematology and oncology.